Australia's Paradigm Biopharmaceuticals falls as HY losses widen

Paradigm Biopharmaceuticals

28/02/2024 02:43

** Shares of Paradigm Biopharmaceuticals  PAR.AX  fall as
much as 4.3% to A$0.335, their lowest level since Feb 7
    ** The Australian late-stage drug developer posts HY total
comprehensive loss attributable of A$49 mln ($32 mln), compared
with a loss of A$32 mln from previous year
    ** HY revenue, however, from continuing activities A$1.3
million, up 7.1% from previous year
    ** Stock has fallen 17.7% this year, as of last close

    ($1 = 1.5314 Australian dollars)

 (Reporting by Sherin Sunny in Bengaluru)
 ((Sherin.Sunny@thomsonreuters.com))